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The current thesis describes the use of isolated limb infusion (ILI) for unresectable 
melanoma or sarcoma of the limb. It is a strategy to deliver regional cytotoxic 
drugs in an equally effective but less invasive fashion than the traditional isolated 
limb perfusion (ILP). 
To date, just a few institutions have reported on the use of ILI, but there is interest 
in initiating a multi-center study in the USA to better determine its efficacy on a 
larger scale. In the future obviously, a randomized controlled trial is needed to study 
the use of ILI versus ILP.1 If these studies produce results similar to those already 
reported, more widespread use of the ILI technique is likely to occur making it the 
preferred treatment option for patients with in-transit melanoma or advanced soft 
tissue sarcoma of the extremity. 
Meanwhile studies have been undertaken that investigate the technical details 
and the pharmacokinetics of the procedure with the aim to improve the outcome 
and safety of the treatment. Microdialysis and saturable dose studies during ILI, 
for instance, have been initiated to monitor the drug uptake by different types of 
tissues in a dynamic fashion.2 Mice models have contributed to the understanding 
of the altered conditions in the isolated limb due to the induced hypoxia and 
acidosis during the procedure. These studies have provided a better insight in the 
melphalan distribution during ILI and have offered the opportunity to optimize the 
drug regimen by decreasing toxicity without loosing efficacy.3-5 Future studies that 
investigate the enhanced synergism of melphalan and actinomycin-D during ILI 
are needed. Furthermore modifications to achieve actual hyperthermia during the 
procedure will be of value, especially in view of implementing high temperatures 
in double ILI.6
The simplicity of the ILI procedure makes it an appealing strategy to test new drug 
regimens.7 The use of fotemustine, for instance, has been investigated in a trial 
using the ILI protocol, but unfortunately this resulted in unacceptable locoregional 
toxicity. More promising seems the use of temozolomide that, in rodent models, 
has shown to be more effective than melphalan.8-10
Some tumors are more chemosensitive due to a favorable biology, whereas other 
tumors possess or have acquired resistance to chemotherapy.11,12 Increasing the 
dose of the cytotoxic agents in these cases does not result in an increased efficacy, 
but it does increase toxicity.4,13 Gene expression signatures can identify these 
tumors resistant to cytotoxic agents and this technique may ultimately provide 
an opportunity to select and  optimize the use of cytotoxic drugs.14 In melanoma 
cell lines, chemotherapy sensitivity signatures using micro-array gene expression 
data combined with in vitro drug response data have been described.15 The gene 
signature obtained from a biopsy sample could not only predict tumor response 
to chemotherapy allowing for optimal drug selection, but could also identify 
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targeted with appropriate agents. A rodent ILP model as a gene delivery system 
showed that tumor response in the isolated setting was superior to intravenous 
or intra-tumoral injection of cytotoxic agents. The minimally invasive nature of ILI 
compared to ILP would clearly be advantageous when this novel delivery system 
is translated into the clinical setting.16,17
Future aims to increase efficacy in patients with a predicted poor response to 
ILI due to tumor burden or chemoresistance are focused on new combination 
therapies relying on synergistic effects, such as increased drug delivery to the 
tumor, selective effects on the tumor vasculature or increased inducement of 
apoptosis.4,7,18 A study using the cytokine TNF-α along with melphalan in the ILI 
protocol, for instance, would be of great value since in ILP the combination has 
clearly been shown to be effective.19,20
Inhibitors of resistance mechanisms serve as potent chemomodulators that can 
enhance the efficacy of regional chemotherapy. Identifying these mechanisms 
of resistance and determining factors that predict resistance are among the 
key challenges in the near future. Currently a number of studies using systemic 
administration of targeting therapies with ILI are running.7 These targeting therapies 
may disrupt various cell signaling pathways that make the tumors more susceptible 
to the effects of cytotoxic agents by which response rates may increase without 
increasing toxicity.12,21,22
Systemic butathione sulfoximine (BSO), for instance, appears to be a promising 
adjunct to melphalan in regional chemotherapy.12,23 Melanoma cells express 
elevated glutathione (GSH) levels,24,25 which have been associated with inactivation 
of melphalan by direct binding to the cytotoxic drug.26-29 BSO reduces intracellular 
GSH which restores the cytotoxic sensitivity and thus potentiates the effect of 
melphalan.12,30-33 
Another potential targeting therapy is the administration of systemic ADH-1 
(Exherin) in combination with melphalan. This strategy has shown marked response 
increase in melphalan resistant tumors.7,21 ADH-1 disrupts the binding interactions 
of increased intracellular N-cadherin, which causes increased proliferation and 
decreased apoptosis of the tumor cells. 
Genetic mutations in the B-raf kinase signaling pathway lead to increased 
proliferation and survival of tumor cells.34 When the B-raf kinase inhibitor Sorafenib 
is used systemically in combination with chemotherapeutic agents in a regional 
therapeutic setting it has been shown to increase responses.35,36
Stat3 inhibition, a downstream target of src kinase, is also currently studied in an 
ILI trial. Stat3 is activated in the majority of the melanoma cell lines and promotes 
tumor growth and survival as well as upregulation of VEGF.37,38 Inhibition of 
src kinase by Dasatinib (Sprycel) may potentiate the effectiveness of traditional 
chemotherapy by blocking the growth of human melanoma cell lines and inducing 
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apoptosis by inhibiting the expression of anti-apoptotic genes like Bcl-2 and 
Bcl-xL.38
As described in this thesis, adoptive transfer of triple (anti-CD3/anti-CD28/
anti-4-1BB) stimulated T-cells in combination with chemotherapeutic agents can 
potentially increase the tumor response during ILI. Triple activated T-cells show a 
decreased apoptotic rate and an increased cytokine secretion compared to single 
(anti-CD3) or double (anti-CD3/anti-CD28) activated T-cells by which they can 
attack malignant cells more effectively. 
Tumor cells may also become resistant to melphalan by increasing DNA 
repair.11,39 A possible area of interest is using inhibitors of DNA repair enzymes 
in conjunction with regional therapy. The DNA repair enzyme O6-alkylguanine-
DNA alkyltransferase (AGT) activity, for instance, is the predominant mechanism 
of resistance to temozolomide.40,41 In agreement with this observation is the 
outcome of a trial in which regional temozolomide, combined with systemic 
O6-benzylguanine (O6BG), an inhibitor of AGT, was compared with temozolomide 
alone. Tumor response in this trial was enhanced after treatment with the drug 
combination, while toxicity remained the same.9,21
The ILI studies described in this chapter will provide a better understanding 
of pharmacokinetic and chemoresistance mechanisms with in the end the 
identification of optimal combinations of therapeutic agents. These developments 
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